Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
Foghorn Therapeutics Inc. (FHTX)
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced key development updates for its Selective ARID1B degrader program which will be presented as part of a Keynote Plenary session at the 8th Annual TPD and Induced Proximity Summit being held October 27-30, 2025, in Boston, MA. The day after the presentation, Foghorn will host a virtual investor event to review pipeline updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs. “We are excited to present significant progress for our Selective ARID1B degrader at this year’s TPD and Induced Proximity Summit. These findings highlight the potential of our Selective ARID1B degrader program to become a new class of drugs for patients with endometrial, gastric, and bladder cancers with high unmet needs,” said Adria
Show less
Read more
Impact Snapshot
Event Time:
FHTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FHTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FHTX alerts
High impacting Foghorn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
FHTX
News
- Foghorn Therapeutics (NASDAQ:FHTX) was given a new $12.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=FHTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- 4D Molecular Therapeutics taps Kristian Humer as CFO [Seeking Alpha]Seeking Alpha
- 4DMT Appoints Kristian Humer as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
FHTX
Earnings
- 11/5/25 - Beat
FHTX
Sec Filings
- 12/4/25 - Form 8-K
- 11/17/25 - Form 4
- 11/7/25 - Form 8-K
- FHTX's page on the SEC website